Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 617 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: blood transfusion Clear all
Completed Phase 3 Interventional Results available

Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial

NCT00072761
View directory record Official record
Conditions
Sickle Cell Anemia, Stroke
Interventions
transfusion therapy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
5 Years to 14 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT01829503
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
decitabine and cytarabine, Supportive Care
Drug · Other
Lead sponsor
Annie Im, M.D.
Other
Eligibility
60 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Results available

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

NCT00003138
View directory record Official record
Conditions
Anemia, Myelodysplastic Syndromes
Interventions
Erythropoietin, Filgrastim, Transfusion
Biological · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
28
States / cities
Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 5, 2026, 5:46 AM EDT
Terminated Phase 3 Interventional

A Study With Imlifidase in Anti-GBM Disease

NCT05679401
View directory record Official record
Conditions
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions
Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
Drug · Procedure
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

Trauma Resuscitation With Low-Titer Group O Whole Blood or Products

NCT05638581
View directory record Official record
Conditions
Wounds and Injuries, Shock, Hemorrhagic
Interventions
LTOWB, Components
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
15 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 5, 2026, 5:46 AM EDT
Completed No phase listed Observational

Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport

NCT00246077
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 11, 2007 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion

NCT03347422
View directory record Official record
Conditions
Cold Agglutinin Disease
Interventions
sutimlimab (BIVV009), placebo
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Georgetown, District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 5, 2026, 5:46 AM EDT
Recruiting Phase 1 Interventional

Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia

NCT07476183
View directory record Official record
Conditions
RPS19 Deficient Diamond-Blackfan Anemia
Interventions
APR-2020
Biological
Lead sponsor
Apriligen, Inc.
Industry
Eligibility
2 Years to 25 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 5, 2026, 5:46 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes

NCT07712562
View directory record Official record
Conditions
Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse, Severe Aplastic Anemia, Refractory, Non-severe Aplastic Anemia
Interventions
Dibotatug (DR-01)
Drug
Lead sponsor
Dren Bio
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
Duarte, California • Palo Alto, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

Selinexor (KPT-330) in Older Patients With Relapsed AML

NCT02088541
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Selinexor, Hydroxyurea, Ara-C
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
60 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
26
States / cities
Los Angeles, California • Sacramento, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 4 Interventional

Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot

NCT00126334
View directory record Official record
Conditions
Myocardial Infarction, Anemia
Interventions
Packed Red Blood Cell Transfusion
Procedure
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Olaratumab in Soft Tissue Sarcoma

NCT01185964
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
Olaratumab, doxorubicin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Not applicable Interventional

A Trial of Restrictive Versus Traditional Blood Transfusion Practices in Burn Patients

NCT01079247
View directory record Official record
Conditions
Burn Injury
Interventions
Restrictive transfusion threshold, Liberal transfusion threshold
Other
Lead sponsor
American Burn Association
Other
Eligibility
18 Years to 90 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Colton, California • Fresno, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 5, 2026, 5:46 AM EDT
Terminated Phase 2 Interventional Results available

GVAX vs. Placebo for MDS/AML After Allo HSCT

NCT01773395
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions
GVAX, Placebo Vaccine, Allogeneic Hematopoietic Stem Cell Transplant, Busulfan, Fludarabine, Tacrolimus, Methotrexate
Biological · Procedure · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 5, 2026, 5:46 AM EDT
Terminated Not applicable Interventional

AO Multicenter Intervention Trial for Prevention of Surgical Site Infection

NCT03380273
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Implementation of the AO Trauma SSI Prevention Bundle
Behavioral
Lead sponsor
AO Clinical Investigation and Publishing Documentation
Other
Eligibility
18 Years to 100 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
Los Angeles, California • Lexington, Kentucky • Worcester, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 5, 2026, 5:46 AM EDT
Completed No phase listed Observational

Transfusing Neonates Based on Platelet Mass

NCT00759980
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Not listed
Lead sponsor
Christiana Care Health Services
Other
Eligibility
Up to 12 Months
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Newark, Delaware • Wilmington, Delaware • Abington, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Not applicable Interventional Results available

Red Cell Storage Duration and Outcomes in Cardiac Surgery

NCT00458783
View directory record Official record
Conditions
Blood Transfusion, Cardiac Surgery
Interventions
Prolonged RBC storage, Short RBC storage
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
3,942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Optimization of Biotinylation Protocol for Studies of Red Blood Cell Survival and Function After Transfusion

NCT06788080
View directory record Official record
Conditions
Measuring Red Blood Cell Survival After Transfusion
Interventions
BioRBC
Drug
Lead sponsor
Vitalant Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 5, 2026, 5:46 AM EDT
Not listed Phase 1 Interventional

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

NCT03385486
View directory record Official record
Conditions
Stage III Melanoma, Stage IV Melanoma
Interventions
TBX-3400
Biological
Lead sponsor
Taiga Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 5, 2026, 5:46 AM EDT
Recruiting Early Phase 1 Interventional

Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery

NCT03849443
View directory record Official record
Conditions
Open Posterior Thoracolumbar Spinal Fusion Procedure
Interventions
Tranexamic Acid Injectable Product (1000 mg intravenous bolus), Vitamin C 250 MG Oral Tablet, Tranexamic Acid 650Mg Tablet
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Umbilical Cord Blood Infusion to Treat Type 1 Diabetes

NCT00305344
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Autologous Umbilical Cord Blood Transfusion, Cord blood
Procedure · Biological
Lead sponsor
University of Florida
Other
Eligibility
1 Year and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 5, 2026, 5:46 AM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 5, 2026, 5:46 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics

NCT06534450
View directory record Official record
Conditions
Aging
Interventions
Sham, Therapeutic Plasma Exchange, IVIG
Device · Drug
Lead sponsor
Dobri Kiprov
Industry
Eligibility
50 Years to 95 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Mill Valley, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 5, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of ECO Conversion System For Red Blood Cells.

NCT00261274
View directory record Official record
Conditions
Anemia
Interventions
A-ECO, Saline
Biological
Lead sponsor
Velico Medical
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
6
States / cities
New Haven, Connecticut • Minneapolis, Minnesota • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 5, 2026, 5:46 AM EDT